Wegovy Cost in New Hampshire: Prices, Insurance, and Savings in 2026

What Wegovy Actually Costs at New Hampshire Pharmacies

The retail price for Wegovy in New Hampshire is $1,349 per month. That figure comes directly from Novo Nordisk's wholesale acquisition cost and holds relatively steady across major NH chains including CVS, Walgreens, and Rite Aid locations in Manchester, Nashua, Concord, and the Seacoast region. Price differences between pharmacies rarely exceed $30 to $50.

This is not a one-time expense. Wegovy is a chronic medication. The STEP-1 trial (N=1,961) demonstrated that participants regained two-thirds of lost weight within one year of stopping semaglutide 2.4 mg, which means most patients need ongoing treatment to maintain results [1]. At $1,349 per month, that comes to $16,188 per year before insurance or discount programs.

Cash-pay patients in New Hampshire should compare prices using tools like GoodRx or RxSaver, though discounts on brand-name Wegovy tend to be modest. The drug is still under patent protection, and no FDA-approved generic semaglutide 2.4 mg injection exists as of mid-2026.

The practical question for most NH residents is not the sticker price. It is how much they will actually pay after insurance, savings cards, or compounded alternatives reduce that number. The sections below break down each path.

New Hampshire Medicaid and Wegovy: No Coverage

New Hampshire Medicaid does not cover Wegovy for chronic weight management. This applies to both traditional Medicaid and the state's Granite Advantage Health Care Program (expanded Medicaid). The New Hampshire Department of Health and Human Services has not added GLP-1 receptor agonists prescribed solely for obesity to its preferred drug list.

This gap is significant. Roughly 130,000 New Hampshire residents are enrolled in Medicaid, according to CMS enrollment data, and the state's adult obesity rate exceeds 30% per CDC BRFSS data [2]. NH Medicaid does cover semaglutide at lower doses (Ozempic, 0.25 mg to 1 mg) when prescribed for type 2 diabetes, but the 2.4 mg formulation branded as Wegovy remains excluded for weight management alone.

There is no current legislative mandate requiring New Hampshire Medicaid to cover anti-obesity medications. Some states, including New York and Connecticut, have added or are considering GLP-1 coverage mandates. New Hampshire has not introduced comparable legislation as of May 2026.

Patients on NH Medicaid who also carry a type 2 diabetes diagnosis should talk to their prescriber about whether semaglutide at a diabetes-indicated dose could be appropriate. That is a separate clinical decision from using the 2.4 mg weight-management dose.

Commercial Insurance Coverage in New Hampshire

Coverage for Wegovy under commercial insurance in New Hampshire varies widely by carrier and plan tier. Anthem Blue Cross Blue Shield, Harvard Pilgrim Health Care, Cigna, and Aetna all offer plans in the state, and each applies its own formulary rules and prior authorization criteria.

Most plans that do cover Wegovy require prior authorization. Typical criteria include a documented BMI of 30 or higher (or BMI ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia), evidence of a failed dietary and exercise intervention lasting 3 to 6 months, and a prescription from a licensed provider. Some plans also require documentation that the patient has tried other weight-management medications first.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend pharmacotherapy as a first-line adjunct to lifestyle modification for patients with BMI ≥30, which can support prior authorization appeals [3].

When a plan does cover Wegovy, typical copays range from $25 to $150 per month on preferred formulary tiers. On non-preferred or specialty tiers, patients may face coinsurance of 25% to 50%, pushing out-of-pocket costs to $337 to $675 per month before reaching their deductible or out-of-pocket maximum.

New Hampshire residents who receive insurance through an employer should check whether their specific plan includes anti-obesity medication coverage. Self-insured employer plans (common among larger companies) are governed by federal ERISA law rather than state insurance mandates, so coverage decisions are made by the employer and their pharmacy benefit manager. Call the number on the back of your insurance card and ask specifically about Wegovy by name, not just "weight loss medication."

The Novo Nordisk Savings Card: How It Works in NH

Novo Nordisk offers a manufacturer savings card for Wegovy that can reduce out-of-pocket costs for commercially insured patients. The program is available to New Hampshire residents who meet the eligibility requirements.

For patients with commercial insurance that covers Wegovy, the savings card can reduce the copay to as low as $0 per month, with a maximum benefit of $500 per 28-day supply. For commercially insured patients whose plan does not cover Wegovy, the card offers a fixed monthly price (typically around $500 per month as of 2026), though this figure can change.

Key restrictions apply. Patients enrolled in Medicare, Medicaid, Tricare, or any other federal or state government-funded insurance program are not eligible. The card also has an annual maximum benefit, which Novo Nordisk adjusts periodically. Patients should verify current terms directly at the Wegovy savings card page through the FDA-approved prescribing information or the manufacturer's website [4].

The savings card requires a valid prescription and an active commercial insurance plan. It cannot be combined with other manufacturer coupons or copay assistance programs. NH residents filling at an in-network pharmacy should present the card at the point of sale along with their insurance card.

For patients paying the full $1,349 per month without insurance, the savings card benefit is more limited. The out-of-pocket reduction brings the price closer to the $500 range rather than eliminating it entirely.

Compounded Semaglutide 2.4 mg in New Hampshire

Compounded semaglutide 2.4 mg is available in New Hampshire through licensed 503A compounding pharmacies. This is the most common cost-reduction strategy for patients who cannot afford brand-name Wegovy and lack adequate insurance coverage.

A 503A pharmacy operates under a patient-specific prescription from a licensed provider. Under federal law (the Drug Quality and Security Act, Section 503A), these pharmacies may compound medications that are not commercially available or when a prescriber documents a clinical need for a compounded version. The FDA's position on compounded semaglutide has evolved; as of early 2026, semaglutide remains on the FDA drug shortage list, which affects compounding eligibility [4].

Prices for compounded semaglutide 2.4 mg in New Hampshire typically start around $199 per month. That figure represents a savings of roughly 85% compared to the $1,349 brand-name list price. Some telehealth platforms and compounding networks charge between $199 and $399 per month depending on the dose, supply duration, and whether consultations are bundled.

Patients considering compounded semaglutide should verify three things. First, that the compounding pharmacy is licensed by the New Hampshire Board of Pharmacy. Second, that it operates as a legitimate 503A or 503B facility. Third, that the prescribing provider has conducted an appropriate medical evaluation, including review of BMI, medical history, and contraindications.

Dr. Robert Kushner, a professor of medicine at Northwestern University's Feinberg School of Medicine and obesity medicine specialist, has stated: "The quality and potency of compounded GLP-1 medications can vary significantly between pharmacies. Patients should ensure they are working with reputable providers who verify third-party testing of their compounded products."

Compounded semaglutide is not FDA-approved. It does not carry the same regulatory oversight as brand-name Wegovy, and patients accept a different risk profile when choosing this option.

Telehealth Access to Wegovy in New Hampshire

New Hampshire permits telehealth prescribing of Wegovy and compounded semaglutide. The state's telehealth laws, updated during and after the COVID-19 public health emergency, allow licensed providers to prescribe controlled and non-controlled medications via audio-video consultations.

Semaglutide is not a controlled substance under federal or New Hampshire law. This simplifies telehealth prescribing. A provider licensed in New Hampshire (or holding an appropriate interstate license) can evaluate a patient, confirm eligibility, and transmit a prescription to an NH pharmacy or a licensed mail-order/compounding pharmacy.

Several national telehealth platforms serve New Hampshire patients for GLP-1 prescriptions. These typically charge a consultation fee ($50 to $199 for an initial visit) plus the cost of the medication itself. Bundled programs that include the consultation, medication, and follow-up monitoring may range from $249 to $499 per month for compounded semaglutide.

The Endocrine Society clinical practice guidelines recommend that prescribers of anti-obesity medications conduct periodic follow-up assessments including weight monitoring, metabolic labs, and side-effect screening [5]. Telehealth platforms that schedule regular check-ins align better with these guidelines than those offering prescription-only services with no ongoing monitoring.

New Hampshire residents in rural areas, including the North Country, Lakes Region, and Upper Valley, benefit most from telehealth access. In-person obesity medicine specialists are concentrated in the southern tier of the state (Manchester, Nashua, the Seacoast), and wait times for new-patient appointments can exceed 8 to 12 weeks.

What STEP-1 Showed About Semaglutide 2.4 mg Efficacy

Understanding what you are paying for helps contextualize the cost. The STEP-1 trial, published in the New England Journal of Medicine in 2021, remains the key efficacy study behind Wegovy's FDA approval [1].

STEP-1 enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) who did not have type 2 diabetes. Participants received either semaglutide 2.4 mg once weekly or placebo, both combined with lifestyle intervention. At 68 weeks, the semaglutide group achieved a mean body weight reduction of 14.9%, compared with 2.4% in the placebo group.

Beyond weight loss, semaglutide 2.4 mg produced clinically meaningful improvements in cardiometabolic markers. Systolic blood pressure decreased by an additional 6.2 mmHg versus placebo. Waist circumference decreased by 13.5 cm versus 4.1 cm. C-reactive protein, a marker of systemic inflammation, dropped by 47% more than placebo.

The SELECT trial (N=17,604), published in 2023, extended these findings to cardiovascular outcomes, demonstrating a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease treated with semaglutide 2.4 mg versus placebo [6]. This trial led to Wegovy receiving an expanded FDA indication for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease.

These results explain why demand for semaglutide remains high despite the price. The drug produces weight loss in the range of 15%, which exceeds what older anti-obesity medications achieved, and it carries documented cardiovascular benefits.

Cheapest Ways to Get Wegovy in New Hampshire: A Ranked Breakdown

New Hampshire residents seeking the lowest cost for semaglutide 2.4 mg have several paths, ranked from least expensive to most expensive.

Compounded semaglutide via 503A pharmacy: Starting at approximately $199 per month. Requires a valid prescription. Not FDA-approved. Verify pharmacy licensure through the New Hampshire Board of Pharmacy.

Wegovy with commercial insurance and savings card: As low as $0 per month copay for eligible commercially insured patients. Requires prior authorization from your insurer and activation of the Novo Nordisk savings card.

Wegovy with commercial insurance (no savings card): Typically $25 to $150 per month on preferred tiers. Higher on specialty tiers, potentially $337 to $675 per month with coinsurance.

Wegovy with savings card only (no insurance coverage): Approximately $500 per month, though terms vary.

Cash pay at NH retail pharmacy: $1,349 per month. No discounts apply at this price point beyond occasional GoodRx coupons offering marginal savings.

The AACE guidelines note that cost is a primary barrier to anti-obesity medication adherence, and clinicians should discuss financial access during treatment planning [3]. New Hampshire patients should bring up cost concerns at their first appointment so their prescriber can factor affordability into the treatment decision.

Side Effects and Monitoring Costs to Factor In

The medication cost is not the only expense. Ongoing monitoring adds to the total outlay, and side effects can generate additional costs.

Gastrointestinal symptoms are the most common adverse effects. In STEP-1, nausea occurred in 44% of semaglutide patients versus 18% on placebo, diarrhea in 30% versus 16%, and vomiting in 24% versus 6% [1]. Most GI side effects are transient and peak during dose escalation (the first 16 to 20 weeks), but some patients require anti-nausea medications such as ondansetron ($10 to $30 per month generic) during this period.

Recommended monitoring includes periodic metabolic panels, lipid panels, and HbA1c testing for patients with prediabetes or diabetes. These labs typically cost $50 to $200 per panel without insurance, or $0 to $50 with most commercial plans. The FDA prescribing information for Wegovy notes monitoring considerations including thyroid function in patients with a personal or family history of medullary thyroid carcinoma [4].

Wegovy carries a boxed warning regarding thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients with a history of pancreatitis should also discuss risks with their prescriber before starting treatment.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "The dose-escalation schedule for semaglutide 2.4 mg is designed to minimize gastrointestinal side effects. Starting at 0.25 mg weekly and increasing every four weeks gives the body time to adapt. Patients who skip the titration schedule experience significantly more nausea and are more likely to discontinue treatment."

Budget an additional $50 to $200 per quarter for labs and follow-up visits when calculating total treatment costs in New Hampshire.